Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Whelan

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Molecular Therapeutics|March 12, 2004
Immunotherapy in anticancer responsesMike Whelan
Current Opinion in Molecular Therapeutics|March 1, 2005
Novel immunotherapeutic approaches to prostate cancerAngus Dalgleish, Mike Whelan
Molecular Diagnosis & Therapy|December 13, 2006
Biomarkers for the development of cancer vaccines: current statusJohn Copier, Mike Whelan, Angus Dalgleish
Drug Discovery Today|March 8, 2003
Cancer immunotherapy: an embarrassment of riches?Mike Whelan, Joseph Whelan, Nick Russell, et al.
Personalized Medicine|May 23, 2018
Biomarkers for development of cancer vaccinesMike Whelan, Graham Ball, Chris Beattie, et al.
Medical Oncology (Northwood, London, England)|August 10, 2004
Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responsesAndreas Lundqvist, Andreas Palmborg, Gawa Bidla, et al.
The Journal of Biological Chemistry|May 9, 2015
Assembly Pathway of Hepatitis B Core Virus-like Particles from Genetically Fused DimersKris Holmes, Dale A Shepherd, Alison E Ashcroft, et al.
BJU International|August 5, 2004
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II studyHardev S Pandha, Robert J John, James Hutchinson, et al.
The New England Journal of Medicine|March 6, 2022
Delivering Pandemic Vaccines in 100 Days - What Will It Take?Melanie Saville, Jakob P Cramer, Matthew Downham, et al.
Vaccine|October 30, 2016
Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 projectHeng Liu, Henderik W Frijlink, Anke Huckriede, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Molecular Therapeutics|March 12, 2004
Immunotherapy in anticancer responsesMike Whelan
Current Opinion in Molecular Therapeutics|March 1, 2005
Novel immunotherapeutic approaches to prostate cancerAngus Dalgleish, Mike Whelan
Molecular Diagnosis & Therapy|December 13, 2006
Biomarkers for the development of cancer vaccines: current statusJohn Copier, Mike Whelan, Angus Dalgleish
Drug Discovery Today|March 8, 2003
Cancer immunotherapy: an embarrassment of riches?Mike Whelan, Joseph Whelan, Nick Russell, et al.
Personalized Medicine|May 23, 2018
Biomarkers for development of cancer vaccinesMike Whelan, Graham Ball, Chris Beattie, et al.
Medical Oncology (Northwood, London, England)|August 10, 2004
Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responsesAndreas Lundqvist, Andreas Palmborg, Gawa Bidla, et al.
The Journal of Biological Chemistry|May 9, 2015
Assembly Pathway of Hepatitis B Core Virus-like Particles from Genetically Fused DimersKris Holmes, Dale A Shepherd, Alison E Ashcroft, et al.
BJU International|August 5, 2004
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II studyHardev S Pandha, Robert J John, James Hutchinson, et al.
The New England Journal of Medicine|March 6, 2022
Delivering Pandemic Vaccines in 100 Days - What Will It Take?Melanie Saville, Jakob P Cramer, Matthew Downham, et al.
Vaccine|October 30, 2016
Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 projectHeng Liu, Henderik W Frijlink, Anke Huckriede, et al.
Pageof 2